

AUG 29 2002



IN 09/732,241

COPY OF PAPERS
ORIGINALLY FILED

10/ Reg for
Recs

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mathai Mammen et al.

Examiner: Raymond Covington

Serial No.: 09/732,241

Group Art Unit: 1625

Filed: December 7, 2000

Docket: 1343.011US1

Title: THERAPEUTIC CARBAMATES

Bet
9-6-02

RESPONSE UNDER 37 CFR § 1.111

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on May 30, 2002, please consider the following remarks.

REMARKS

Applicants respectfully request reconsideration of the rejection of the claims in view of the remarks presented herein. Claims 1-52 are pending.

§112 Rejections

Claim 22 was rejected under 35 U.S.C. § 112, second paragraph, as indefinite. This rejection is respectfully traversed.

The Examiner stated that the phrase "any one of formula A1-A590 shown herein above" renders claim 22 indefinite. It is respectfully pointed out that claim 22 was amended in the previous amendment and response filed 07 February 2002; claim 22 now reads, "The compound of claim 1 or 2 wherein L₂ has any one of the formulas A1-A590 in Table 1." Thus, claim 22 does not include the phrase identified by the Examiner as indefinite. Accordingly, withdrawal of the rejection of claim 22 under 35 U.S.C. § 112, second paragraph, is respectfully requested.

The following remarks are also provided in support of the patentability of claim 22. Claim 22 recites specific values for L₂ and depends from claims 1 and 2. Both claims 1 and 2 recite compounds comprising a group L₂. Thus, there is antecedent basis for "L₂." Additionally, formulas A1-A590 fall within the definition of L₂ recited in claims 1 and 2. Thus, it is respectfully submitted that there is sufficient antecedent basis for the specific L₂ values recited in